Hims & Hers Health (NYSE:HIMS) Trading 8.9% Higher - What's Next?

Key Points

• Hims & Hers Health shares rose 8.9%, reaching a peak of $52.02, although trading volume was down 39% from average levels.
• Recent analyst reports reflect a mix of opinions with two Buy ratings, eight Holds, and three Sells, while Truist Financial lowered its price target from $48.00 to $37.00.
• The company's latest earnings report showed a revenue increase of 72.6% year-over-year, but earnings per share missed estimates at $0.17.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares shot up 8.9% during trading on Thursday . The stock traded as high as $51.16 and last traded at $52.02. 20,035,647 shares were traded during mid-day trading, a decline of 39% from the average session volume of 33,041,816 shares. The stock had previously closed at $47.78.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of research reports. Truist Financial cut their price objective on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a report on Monday, August 18th. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a research report on Monday, June 23rd. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Finally, Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Trading Up 8.4%

The business's fifty day simple moving average is $50.03 and its two-hundred day simple moving average is $45.14. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The stock has a market capitalization of $11.70 billion, a P/E ratio of 64.73, a P/E/G ratio of 3.23 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm's revenue was up 72.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $45.06, for a total value of $5,773,402.62. Following the completion of the transaction, the chief executive officer owned 89,521 shares of the company's stock, valued at approximately $4,033,816.26. This represents a 58.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $43.69, for a total transaction of $505,973.89. Following the transaction, the chief financial officer directly owned 116,806 shares of the company's stock, valued at $5,103,254.14. This represents a 9.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,384,728 shares of company stock valued at $71,149,098 in the last three months. 13.71% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently made changes to their positions in the company. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $26,000. Quaker Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter valued at about $29,000. Bessemer Group Inc. increased its position in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after buying an additional 312 shares in the last quarter. Skandinaviska Enskilda Banken AB publ increased its stake in shares of Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock worth $37,000 after purchasing an additional 600 shares in the last quarter. Finally, Spire Wealth Management purchased a new stake in shares of Hims & Hers Health during the second quarter worth approximately $42,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.